Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trelegy Ellipta in Hospitalized COPD Exacerbations
NCT05292053Phase 4Completed
- Sponsor
- Baylor Scott & White Research Institute
- Start
- Jul 2022
- Primary completion
- Sep 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of fluticasone in chronic obstructive pulmonary disease (COPD), sponsored by Baylor Scott & White Research Institute. Started Jul 2022; status: completed.
02
Drugs
fluticasone
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05292053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05292053.